Skip to main content

Table 2 Poly Q sequence patterns and AIB1 amplification level in MCF7 and its variants

From: AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines

Cell linea

amplification

Sequence patterns

Pattern

(Q)n

Frequency

MCF-7

22.3

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

7/7

MCF-7 P19

18.7

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

7/9

  

(CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

2

29

1/9

  

(CAG)5CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

3

28

1/9

MCF-7 P72

22.8

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

5/7

  

(CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

4

25

1/7

  

(CAG)3CAA(CAG)7(CAACAG)3(CAACAGCAG)2CAA

5

24

1/7

LCC1

13.5

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

7/9

  

(CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

4

25

1/9

  

(CAG)3CAA(CAG)14(CAACAG)2(CAACAGCAG)2CAA

6

29

1/9

LCC2

14.6

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

4/5

  

CAG(CAACAG)3(CAACAGCAG)2CAA

7

14

1/5

LCC9

15.6

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

7/8

  

(CAG)3CAA(CAG)2CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

8

29

1/8

LY-2

19.9

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

9/10

  

(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

9

28

1/10

R27

19.4

(CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA

1

26

8/9

  

(CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

4

25

1/9

MDA-MB435

1.3

(CAG)3CAA(CAG)2CAA(CAG)11(CAACAG)2(CAACAGCAG)2CAA

10

29

2/8

  

(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

9

28

3/8

  

(CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

1

26

2/8

  

(CAG)6CAA(CAG)8(CAACAG)2(CAACAGCAG)2CAA

11

26

1/8

LCC6

2.0

(CAG)3CAA(CAG)2CAA(CAG)10(CAACAG)2(CAACAGCAG)2CAA

12

28

1/9

  

(CAG)3CAA(CAG)2CAA(CAG)6(CAACAG)3(CAACAGCAG)2CAA

13

26

1/9

  

(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

9

28

3/9

  

(CAG)3CAA(CAG)2CAA(CAG)10(CAACAG)3(CAACAGCAG)2CAA

14

30

1/9

  

(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

15

28

1/9

  

(CAG)3CAA(CAG)2CAA(CAG)11(CAACAG)2(CAACAGCAG)2CAA

10

29

1/9

  

(CAG)3CAA(CAG)2CAACAGCAA(CAG)8(CAACAG)2(CAACAGCAG)2CAA

16

28

1/9

ZR-75-1

1.5

(CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

2

29

6/7

  

(CAG)5CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

3

28

1/7

AK-47

1.4

(CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

2

29

2/8

  

(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

11

28

5/8

  

(CAG)5CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA

15

27

1/8

A1N4

2.0

(CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

2

29

20/41

  

(CAG)4CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA

17

27

21/41

  1. aLCC1: estrogen independent and responsive which is selected for growth in vivo without estrogens; LCC2: selected from LCC1 by treatment with 4-OH TAM; LCC9: selected from LCC1 by treatment with ICI 182780, resistant to ICI182780 and 4-OH TAM:, LY-2: selected for resistance to 4-OH TAM, KEO and LY 117018; R27: able to grow in the presence of 4-OH TAM. LCC6 is the more aggressive variant of MD-MB435. AK-47 is the variant derived from ZR-75-1. A1N4 is a normal breast cell line. The parental sequence patterns are in bold.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us